All In Biotech

Drug Trial Radar · NCT06045806

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

79

Actual

Start

Oct 16, 2023

Primary completion

Aug 11, 2025

Study completion Nov 20, 2029

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb; 2seventy bio
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

Conditions

  • Multiple Myeloma

Interventions

  • idecabtagene vicleucelBiological

    Specified dose on specified days

  • LenalidomideDrug

    Specified dose on specified days

  • FludarabineDrug

    Specified dose on specified days

  • CyclophosphamideDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to approximately 50 months after the first participant is randomized

Locations

101 sites in 18 countries. Site status is shown where the registry gives one.

  • Local Institution - 0131

    Los Angeles, California

  • Local Institution - 0126

    Orange, California

  • Local Institution - 0113

    Sacramento, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • AdventHealth Orlando

    Orlando, Florida

  • Local Institution - 0121

    Atlanta, Georgia

  • Local Institution - 0104

    Atlanta, Georgia

  • Local Institution - 0151

    Boston, Massachusetts

  • Ascension Providence Hospital

    Southfield, Michigan

  • M Health Fairview Clinics and Surgery Center

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Irving Medical Center

    New York, New York

  • Novant Health Cancer Institute - Elizabeth

    Charlotte, North Carolina

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Local Institution - 0132

    Philadelphia, Pennsylvania

  • Local Institution - 0124

    Austin, Texas

  • Local Institution - 0109

    Houston, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Local Institution - 0007

    Camperdown, New South Wales, Australia

  • Local Institution - 0005

    Brisbane, Queensland, Australia

  • Local Institution - 0004

    Melbourne, Victoria, Australia

  • Local Institution - 0006

    Melbourne, Victoria, Australia

  • Local Institution - 0008

    Melbourne, Victoria, Australia

  • Local Institution - 0011

    Murdoch, Western Australia, Australia

  • Local Institution - 0089

    Salzburg, Austria

  • Local Institution - 0090

    Vienna, Austria

  • Local Institution - 0083

    Anderlecht, Bruxelles-Capitale, Région de, Belgium

  • Local Institution - 0084

    Brussels, Bruxelles-Capitale, Région de, Belgium

  • Local Institution - 0144

    Brussels, Bruxelles-Capitale, Région de, Belgium

  • Local Institution - 0133

    Edmonton, Alberta, Canada

  • Local Institution - 0001

    Hamilton, Ontario, Canada

  • Local Institution - 0134

    Montreal, Quebec, Canada

  • Local Institution - 0070

    Odense, Region Syddanmark, Denmark

  • Local Institution - 0082

    Paris, France

  • Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE

    Toulouse, France

  • Local Institution - 0047

    Pessac, Aquitaine, France

  • Institut Paoli-Calmettes

    Marseille, Bouches-du-Rhône, France

  • Local Institution - 0031

    Paris, Île-de-France Region, France

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.